Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19.
Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19.
复制标题
DOI：
10.2174/0929867327666200721161840
复制
发表时间：
2021
影响因子：
4.1
通讯作者：
Rahman KM
中科院分区：
文献类型：
--
作者：
Laws M;Surani YM;Hasan MM;Chen Y;Jin P;Al-Adhami T;Chowdhury M;Imran A;Psaltis I;Jamshidi S;Nahar KS;Rahman KM
新型冠状病毒（SARS-CoV-2）大流行造成了全球公共卫生紧急情况。这一流行病正在造成严重的发病率、死亡率和重大的经济损失。目前，还没有获得批准的COVID-19治疗方法，开发新疫苗可能需要至少12-18个月。因此，迫切需要找到能够尽快进展到临床开发的新疗法。重新利用监管机构批准的药物和具有已知安全性的实验药物可以提供重要的化合物库，这些化合物可以快速跟踪到临床开发。在全球范围内，已经注册了500多项涉及重新用途药物的临床试验，并启动了150多项临床试验，其中包括世界卫生组织（世卫组织）支持的一些临床试验。这篇综述旨在作为研究小分子疗法治疗COVID-19的指南;它讨论了SARS-CoV-2感染周期并确定了有希望的病毒治疗靶点，报告了一些有希望的预批准的小分子药物，参考了全球150多项临床试验，并对该领域的未来提供了展望。
The novel coronavirus (SARS-CoV-2) pandemic has created a global public health emergency. The pandemic is causing substantial morbidity, mortality and significant economic loss. Currently, no approved treatments for COVID-19 are available, and it is likely to take at least 12-18 months to develop a new vaccine. Therefore, there is an urgent need to find new therapeutics that can be progressed to clinical development as soon as possible. Repurposing regulatory agency-approved drugs and experimental drugs with known safety profiles can provide important repositories of compounds that can be fast-tracked to clinical development. Globally, over 500 clinical trials involving repurposed drugs have been registered, and over 150 have been initiated, including some backed by the World Health Organisation (WHO). This review is intended as a guide to research into small-molecule therapies to treat COVID-19; it discusses the SARS-CoV-2 infection cycle and identifies promising viral therapeutic targets, reports on a number of promising pre-approved small-molecule drugs with reference to over 150 clinical trials worldwide, and offers a perspective on the future of the field.
登录
查看更多内容
影响因子：
5.9
作者：
Carr AC;Maggini S
通讯作者：
Maggini S
影响因子：
3.7
作者：
Akerström S;Gunalan V;Keng CT;Tan YJ;Mirazimi A
通讯作者：
Mirazimi A
影响因子：
2.8
作者：
DAVELAAR, FG;VANDENBOS, J
通讯作者：
VANDENBOS, J
DOI：
10.1016/j.jcv.2004.03.003
发表时间：
2004-09
期刊：
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
影响因子：
--
作者：
Chen F;Chan KH;Jiang Y;Kao RY;Lu HT;Fan KW;Cheng VC;Tsui WH;Hung IF;Lee TS;Guan Y;Peiris JS;Yuen KY
通讯作者：
Yuen KY
影响因子：
6.4
作者：
Agostini ML;Andres EL;Sims AC;Graham RL;Sheahan TP;Lu X;Smith EC;Case JB;Feng JY;Jordan R;Ray AS;Cihlar T;Siegel D;Mackman RL;Clarke MO;Baric RS;Denison MR
通讯作者：
Denison MR